CEO of SK Biosciences receiving KOSPI listing contract▶ Click here for a larger view
As SK Biosciences went public on the 18th, as the price ceiling rose to the limit, employees who received employee stock ownership and stock purchase rights (stock options) earned an average of 700 million won per person.
According to SK Bioscience, 4,494 million shares, 19.57% of the total allocation, were allocated to the employee stock ownership association in the public offering stock offer made on the 9th.
According to the company, 628 members participated in the subscription to employee stock ownership.
If the number of subscription members is 600, it is estimated that an average of 7,150 shares will be allocated per person.
On the first day of listing, SK Bioscience’s stock price ended at 169,000 won, a 160% increase from the public offering price (65,000 won).
The initial price was determined to be twice the public offering price (130,000 won), and the so-called’tasang’, which rises to the price limit (30.00%), succeeded.
The valuation gain per share, applying the closing price on the 18th, is estimated to be 104,000 won, and the average valuation gain earned per employee stockholder is estimated to be about 7443.6 million won.
SK Biopharmaceuticals, which held an upper limit for three consecutive days after listing[326030] Assuming that the case is followed, the valuation gain per member may exceed 1.5 billion won.
However, some point out that the valuation gains from a short-term perspective are of little significance because the newly issued employee stocks cannot be sold for one year after listing.
In fact, in the case of SK Biopharm, the stock price of SK Biopharm rose to the 200,000 won level at the beginning of the listing, but has now fallen to the 110,000 won level.
The gain on the valuation of the stock purchase right granted to executives is expected to reach a maximum of tens of billions of won.
SK Biosciences successfully listed on KOSPI▶ Click here for a larger view
A total of 546,000 shares were issued by the company to four executives, including CEO Ahn Jae-yong. The exercise price of the claim is 9,154 won.
The stock purchase right is the right to buy a specific stock at a set price, and if the market price is higher than the exercise price, you can make a profit by that amount.
It is estimated that the valuation gain of the stock purchase right applied at the morning of the 18th will reach 87.3 billion won. By executive, the amount ranges from 17.5 billion won to 34.9 billion won.
[연합뉴스]
Copyrights ⓒ Yonhap News. Unauthorized reproduction and redistribution prohibited